| 证券代码 | PTLA.O |
| 证券名称 | Portola Pharmaceuticals Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2013-05-22 |
| 首发价格(元) | 14.5 USD |
| 首发数量(股) | 8422758 |
| 首发募资额(元) | 122,129,991.00 USD |
| 首发主承销商 | Morgan Stanley & Co. LLC,Credit Suisse Securities (USA) LLC |
| 货币单位 | USD |
| 公司名称 | Portola Pharmaceuticals, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 270 E. Grand Avenue, South San Francisco, California, USA |
| 成立日期 | 2003-09 |
| 董事会主席 | Hollings C. Renton |
| 公司属地 | United States 美国 |
| 公司网址 | www.portola.com |
| 电话 | +1 (650) 246-7000 |
| 传真 | +1 (650) 246-7376 |
| 公司简介 | Portola Pharmaceuticals, Inc. is a biopharmaceutical company developing products that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three investigational programs, including: betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and, cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola also is co-developing Syk-selective inhibitors for inflammatory conditions. |